免疫抑制剤の体内動態と薬効の速度論的解析に基づく個別化投与設計に関する研究

DOI Web Site Web Site 被引用文献1件 参考文献39件

書誌事項

タイトル別名
  • Individualized Dosage Regimen of Immunosuppressive Drugs Based on Pharmacokinetic and Pharmacodynamic Analysis
  • メンエキ ヨクセイザイ ノ タイナイ ドウタイ ト ヤッコウ ノ ソクドロンテキ カイセキ ニ モトズク コベツカ トウヨ セッケイ ニ カンスル ケンキュウ

この論文をさがす

抄録

  The calcineurin inhibitors cyclosporine and tacrolimus are widely used to prevent allograft rejection after transplantation. Since these drugs have narrow therapeutic windows and show considerable pharmacokinetic variability, therapeutic drug monitoring (TDM) is essential to avoid adverse effects such as nephrotoxicity while maximizing immunosuppressive efficacy. On the other hand, some patients experience acute rejection episodes or postoperative complications despite achieving therapeutic blood drug levels. Therefore, pharmacokinetic and pharmacodynamic factors by which to establish individualized dosage adjustment for these drugs should be identified. Recently, it was recognized that pharmacogenomics has the potential to facilitate personalized medicine by translating knowledge of human genome variability into rational therapeutics. In this paper, we review the population pharmacokinetic and pharmacogenomic analysis of tacrolimus, focusing on an efflux transporter P-glycoprotein (multidrug resistance 1 [MDR1/ABCB1]) and drug-metabolizing enzymes cytochrome P450 (CYP) 3A4 and 3A5, and describe Bayesian forecasting to individualize the tacrolimus dose in de novo living-donor liver transplant recipients. Furthermore, the pharmacodynamic properties of tacrolimus and cyclosporine, which were evaluated by measuring calcineurin phosphatase activity in peripheral blood mononuclear cells, are reviewed in relation to an optimal monitoring strategy as well as a rational dosage regimen for these drugs.<br>

収録刊行物

  • 薬学雑誌

    薬学雑誌 127 (7), 1081-1089, 2007-07-01

    公益社団法人 日本薬学会

被引用文献 (1)*注記

もっと見る

参考文献 (39)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ